[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.120.181. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 264
Citations 0
Comment & Response
June 2014

Are High Prices a Barrier to Human Papillomavirus Vaccination in the United States? Not in Italy

Author Affiliations
  • 1Centre for Health Economics, CESAV, IRCCS Mario Negri Institute for Pharmacological Research, Bergamo, Italy
JAMA Pediatr. 2014;168(6):584. doi:10.1001/jamapediatrics.2014.49

To the Editor A very recent survey in Italy1 showed that the main hurdles to human papillomavirus vaccination among adolescent Italian girls are fear of adverse events, scant confidence in new vaccines, and a general lack of information.

In contrast to the interesting review on the barriers to the vaccine in the United States,2 the high cost of the vaccine was not considered a hurdle in Italy. This probably reflects the Italian experience of the price of human papillomavirus vaccines since the start of the public campaign in 2008.

First Page Preview View Large
First page PDF preview
First page PDF preview
×